Trials / Completed
CompletedNCT01226732
A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors
A Phase I Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- SCRI Development Innovations, LLC · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators propose this Phase I trial of the combination of AUY922 and capecitabine to determine the maximum tolerated dose (MTD) in patients with advanced solid tumors. This combination treatment has potential applicability in tumor types where capecitabine or fluorouracil is a treatment option, including colorectal and breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capecitabine | Taken orally twice daily on Days 1 through 14 of 21 day cycle. |
| DRUG | Hsp90 Inhibitor AUY 922 | IV infusion over 60 minutes on Days 1, 8, and 15 of each 21 day cycle |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2013-07-01
- Completion
- 2014-06-01
- First posted
- 2010-10-22
- Last updated
- 2022-03-08
- Results posted
- 2015-01-14
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01226732. Inclusion in this directory is not an endorsement.